MDM2 gene amplification and protein expressions in colon carcinoma: is targeting MDM2 a new therapeutic option?

The p53 tumor suppressor: A master regulator of diverse cellular processes and therapeutic target in cancer

(2010) Marianne Farnebo et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Reactivation of p53 by Novel MDM2 Inhibitors: Implications for Pancreatic Cancer Therapy

(2010) A.S. Azmi et al.   CURRENT CANCER DRUG TARGETS

MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function

(2010) Asfar S. Azmi et al.   EUROPEAN JOURNAL OF CANCER

Cytoplasmic tethering is involved in synergistic inhibition of p53 by Mdmx and Mdm2

(2009) Chihiro Ohtsubo et al.   CANCER SCIENCE

MDM2 SNP309 Associates With Accelerated Pancreatic Adenocarcinoma Formation

(2009) Lukasz F. Grochola et al.   PANCREAS

Small-molecule inhibitors of MDM2 as new anticancer therapeutics

(2009) Michael P. Dickens et al.   SEMINARS IN CANCER BIOLOGY

Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction to Reactivate p53 Function: A Novel Approach for Cancer Therapy

(2008) Sanjeev Shangary et al.   Annual Review of Pharmacology and Toxicology

Polysomy 17 in Breast Cancer: Clinicopathologic Significance and Impact on HER-2 Testing

(2008) Isabelle Vanden Bempt et al.   JOURNAL OF CLINICAL ONCOLOGY

Fluorescence in situ hybridization for MDM2 gene amplification as a diagnostic tool in lipomatous neoplasms

(2008) Joshua Weaver et al.   MODERN PATHOLOGY

MDM2 Gene Amplification Is Correlated to Tumor Progression but not to the Presence of SNP309 or TP53 Mutational Status in Primary Colorectal Cancers

(2008) A. Forslund et al.   MOLECULAR CANCER RESEARCH

Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition

(2008) S. Shangary et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA